BioCentury
ARTICLE | Financial News

Vertex falls after earnings miss

November 3, 2012 1:08 AM UTC

Vertex Pharmaceuticals Inc. (NASDAQ:VRTX) fell $5.47 (11%) to $45.01 on Friday after reporting 3Q12 earnings late Thursday that missed the Street's revenue and EPS estimates. The move translates into a $1.2 billion loss in the biotech's market cap, which is now $9.7 billion. Vertex reported total revenues for the quarter of $336 million, missing by $41 million the Street's estimate of $377 million. ...